• $5.2M
    Market Cap
  • -80.69%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 57
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus

U.S. stock futures traded mixed on Tuesday as the Santa Claus rally resumed after Monday's declines. Major indices showed minimal movement with the S&P 500 and Nasdaq 100 slightly lower in premarket trading. Key movers included Fonar Corp surging 24.49% on a take-private deal announcement, TEN Holdings jumping 16.31% on a private placement, Boeing rising 0.58% following an $8.6 billion Pentagon contract, and Freeport-McMoRan gaining 1.36% as copper prices hit record highs. The Fed is expected to hold rates steady in January with 83.9% probability.

12/30/2025, 5:21 AM • Benzinga

Why Is Dermata Therapeutics Stock Surging Wednesday?

Dermata Therapeutics (NASDAQ: DRMA) stock surged 20.10% on Wednesday following the announcement of a $12.4 million private placement offering. The company will issue 2,022,062 common shares and warrants priced at $2.04 per share, with expected gross proceeds of $4.1 million. If warrants are fully exercised, the company could raise an additional $8.3 million. Net proceeds will fund consumer research, OTC acne kit launch activities, and working capital. The stock is trading near its 52-week low of $1.96.

12/24/2025, 11:32 AM • Benzinga

Peers

Statistics

More
Day Range
$1.30
$1.40
$1.36
1-Year Range
$0.59
$7.06
$1.36
Latest Close$1.36
Change
+$0.02 (+1.47%)
Volume89,489
Market Cap$5.2M
Shares Outstanding4.0M
P/E (TTM)-0.30
Diluted EPS (TTM)-$4.29
Enterprise Value-$1.7M

Information as of 06/02/2026

Company Profile

DERMATA THERAPEUTICS INC
https://www.dermatarx.com
$5.2M
Market Cap
-$1.7M
Net Income
Sector: Healthcare
Industry: Biotechnology
3525 Del Mar Heights Rd., San Diego, CA, United States, 92130
858 800 2543

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Key Executives

  • Christopher J. Nardo
  • Kyri K. Van Hoose
  • Gerald T. Proehl
  • David F. Hale
  • Maria Bedoya Toro Munera

Current Ownership Distribution

  • Insiders3.0M (61.66%)
  • Institutions1.3M (26.61%)
  • Mutual Funds573,178 (11.73%)
  • Other0 (0.00%)